Pacira BioSciences Q4 Earnings Call Highlights [Yahoo! Finance]
Pacira BioSciences, Inc. (PCRX)
Last pacira biosciences, inc. earnings: 2/20 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacira.com
Company Research
Source: Yahoo! Finance
growth), executed $50M of share repurchases, and guided 2026 revenue to $745–$770M with EXPAREL sales of $600–$620M and non-GAAP gross margins of 77–79%. Commercial momentum was driven by the NOPAIN Act and broader payer uptake—Pacira reported ~ 102 million covered lives at year-end (˜110M in early 2026) and 7% Q4 volume growth in its top five states, though GPO discounting partially offset revenue gains. Management expanded the company's IP and international runway—a volume-limited settlement with Fresenius provides visibility through 2039, patent families grew to 21, and an LG Chem pact targets APAC commercialization (revenue from 2027)—while 2026 clinical catalysts include interim readouts for ZILRETTA and iovera° and 52-week data for PCRX-201. Interested in Pacira BioSciences, Inc.? Here are five stocks we like better. Pacira BioSciences (NASDAQ:PCRX) executives used the company's fourth-quarter and full-year 2025 earnings call to highlight what CEO Frank Lee described as
Show less
Read more
Impact Snapshot
Event Time:
PCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCRX alerts
High impacting Pacira BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
PCRX
News
- Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare ConferenceGlobeNewswire
- Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)GlobeNewswire
- Assessing Pacira BioSciences (PCRX) Valuation After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
PCRX
Earnings
- 2/26/26 - Miss
PCRX
Sec Filings
- 2/26/26 - Form S-8
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- PCRX's page on the SEC website